Spiderwort develops cellulose-based biomaterials to create scaffolds for regenerative medicine applications, including spinal cord injury repair and facial tissue augmentation. Their products, CelluBridge™ and CelluJuve®, aim to enhance tissue regeneration and aesthetic outcomes by providing a supportive framework for cellular growth.
Funding
$16M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Spinal cord injuries and facial tissue damage present significant challenges in regenerative medicine, often resulting in incomplete healing and functional deficits. Current treatment options may lack the ideal structural support needed to facilitate effective tissue regeneration and restoration of function.
Solution
Spiderwort develops cellulose-based biomaterials engineered into scaffolds designed to promote tissue regeneration in spinal cord injuries and facial tissue augmentation. Their CelluBridge™ scaffold aims to provide a supportive matrix for cellular growth and repair within the spinal cord. CelluJuve® is designed as a dermal filler to augment facial tissue and promote rejuvenation by providing a framework for tissue integration and collagen production. These plant-based biomaterial platforms offer a potential framework for advances in regenerative medicine, tissue engineering, and medical aesthetics.
Target Audience
The primary target audience includes medical professionals in regenerative medicine, tissue engineering, and medical aesthetics, specifically those focused on spinal cord injury treatment and facial reconstruction.
Features
- CelluBridge™: A cellulose-based scaffold designed to support the repair and regeneration of the spinal cord.
- CelluJuve®: A cellulose-based dermal filler designed to support facial tissue augmentation and rejuvenation.
- Proprietary technology utilizes cellulose-based biomaterials to engineer scaffolds.
- Plant-based biomaterial platform.